News

Video

Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study

Author(s):

Saad Usmani, MD, MBA, FACP, FASCO

Dr. Saad Usmani discusses the results of the Phase 3 CEPHEUS study, which evaluated the combination of daratumumab with bortezomib/lenalidomide/dexamethasone (D-VRd) in transplant-ineligible or transplant-deferred patients with newly diagnosed multiple myeloma, highlighting its impact on progression-free survival and minimal residual disease negativity.

Related Videos
Glofit-GemOX
4 experts are featured in this series.
Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients With Relapsed or Refractory Waldenström Macroglobulinemia: Results From the Phase 1 CaDAnCe-101 Study
Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia
Michael R. Bishop, MD
Analyses of Minimal Residual Disease (MRD) Negativity Dynamics in the Phase 3 Imroz Study
Mansi R. Shah, MD
Elacestrant real-world progression-free survival (rwPFS) of adult patients with ER+/HER2-, advanced breast cancer: a retrospective analysis using insurance claims in the United States
DB-12
Related Content
Rafael Fonseca, MD
December 30th 2024

Working on the Frontlines of a Revolution in Multiple Myeloma Care

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Smoldering Myeloma
December 11th 2024

Cilta-Cel Leads to 100% MRD-Negativity Rate in High-Risk Smoldering Multiple Myeloma

Paul G. Richardson, MD
October 2nd 2023

Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma

ASH Annual Meeting | Image Credit: ©alionaprof – stock.adobe.com
December 10th 2024

Isa-RVd Induction Provides Significant PFS Benefit in Newly Diagnosed Multiple Myeloma

ASH Annual Meeting | Image Credit: © Tatiana Shepeleva – stock.adobe.com
December 10th 2024

Lisaftoclax Plus Pd Yields High ORRs and Shows Encouraging Safety Profile in RRMM